Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Assist Reprod Genet ; 38(1): 71-78, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33070223

RESUMO

PURPOSE: Laevo (l)-carnitine plays important roles in reducing the cytotoxic effects of free fatty acids by forming acyl-carnitine and promoting beta-oxidation, leading to alleviation of cell damage. Recently, the mitochondrial functions in morula has been shown to decrease with the maternal age. Here, we assessed the effect of l-carnitine on mitochondrial function in human embryos and embryo development. METHODS: To examine the effect of L-carnitine on mitochondrial function in morulae, 38 vitrified-thawed embryos at the 6-11-cell stage on day 3 after ICSI were donated from 19 couples. Each couple donated two embryos. Two siblings from each couple were divided randomly into two groups and were cultured in medium with or without 1 mM L-carnitine. The oxygen consumption rates (OCRs) were measured at morula stage. The development of 1029 zygotes cultured in medium with or without L-carnitine was prospectively analyzed. RESULTS: Addition of L-carnitine to the culture medium significantly increased the OCRs of morulae and improved the morphologically-good blastocyst formation rate per zygote compared with sibling embryos. Twenty healthy babies were born from embryos cultured in L-carnitine-supplemented medium after single embryo transfers. CONCLUSION(S): L-carnitine is a promising culture medium supplement that might be able to counteract the decreased mitochondrial function in human morula stage embryos.


Assuntos
Blastocisto/metabolismo , Carnitina/farmacologia , Desenvolvimento Embrionário/efeitos dos fármacos , Mitocôndrias/metabolismo , Blastocisto/efeitos dos fármacos , Meios de Cultura/química , Técnicas de Cultura Embrionária , Embrião de Mamíferos , Desenvolvimento Embrionário/genética , Feminino , Humanos , Mitocôndrias/efeitos dos fármacos , Oxirredução/efeitos dos fármacos , Consumo de Oxigênio/efeitos dos fármacos , Transferência de Embrião Único , Zigoto/efeitos dos fármacos , Zigoto/crescimento & desenvolvimento
2.
Gynecol Endocrinol ; 34(8): 684-688, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29378447

RESUMO

Age-dependent decline of mitochondrial function has been proposed to be a main cause of decline of embryo quality. Then, l-carnitine plays important roles in reducing the membranous toxicity of free-fatty acids by forming acyl-carnitine and promoting ß-oxidation, preventing cell damage. Recent research revealed that l-carnitine played important roles in vitro in oocyte growth, oocyte maturation and embryo development. However, such beneficial effects of l-carnitine in vivo have yet to be verified. The effect of oral l-carnitine supplementation on embryo quality and implantation potential was examined. A total of 214 patients were included in this study. They all previously received in vitro fertilization-embryo transfer (IVF-ET) and failed to conceive. Then they were administered l-carnitine for 82 days on average and underwent IVF-ET again. There were no significant differences in the total number of retrieved oocytes, and their maturation and fertilization rates between before and after l-carnitine administration. The quality of embryos on Days 3 and 5 after insemination was improved following l-carnitine administration (p < .05) in cycles after l-carnitine administration compared with previous cycles. Healthy neonates were born after IVF-ET following l-carnitine administration. Our data suggested that oral administration of l-carnitine to fertility patients improved the developmental competence of their oocytes after insemination.


Assuntos
Carnitina/uso terapêutico , Desenvolvimento Embrionário/efeitos dos fármacos , Fertilização in vitro/estatística & dados numéricos , Infertilidade Feminina/tratamento farmacológico , Administração Oral , Adulto , Carnitina/farmacologia , Feminino , Humanos , Falha de Tratamento
3.
Gynecol Endocrinol ; 30(5): 359-62, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24628045

RESUMO

The aim of this study was to evaluate the efficacy of oral melatonin supplementation on oocyte and embryo quality in patients in an assisted reproductive technologies program. All patients were treated for at least 2 weeks with melatonin (3 mg/day). To evaluate the cumulative effect of melatonin supplementation, we compared cycle outcomes between the first (no supplementation) and second cycles (melatonin supplementation) of patients who completed two treatment cycles. There were no significant differences in maturation rates (p = 0.50), blastocyst rates (p = 0.75), and the rate of good quality blastocysts (p = 0.59) between the first and second cycles. The fertilization rate of ICSI was higher in the second cycle than that in the first cycle (69.3 versus 77.5%). Being limited to patients with a low fertilization rate in the first cycle (<60%), the fertilization rate dramatically increased after melatonin treatment (35.1 versus 68.2%). The rate of good quality embryos also increased (48.0 versus 65.6%). An important finding in our study was that oral melatonin supplementation can have a beneficial effect on the improvement of fertilization and embryo quality and this may have occurred due to a reduction in oxidative damage.


Assuntos
Fertilização in vitro/métodos , Infertilidade Feminina/tratamento farmacológico , Melatonina/administração & dosagem , Oócitos/efeitos dos fármacos , Administração Oral , Adulto , Feminino , Humanos , Masculino , Oócitos/fisiologia , Gravidez
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA